Celcuity rises on gedatolisib on top-line data in breast cancer |

Slzii.com

0.019879817962646

As Celcuity Inc. awaits a U.S. FDA approval decision for gedatolisib in HER-positive, HER2-negative, PIK3CA wild-type advanced breast cancer...